Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$7.33 -2.1%	$7.89	$2.28 ▼ $9.01	$1.11B	1.73	1.49 million shs	1.27 million shs
AMPH Amphastar Pharmaceuticals	$23.35 +1.6%	$27.96	$22.64 ▼ $53.96	$1.09B	0.79	462,248 shs	735,039 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
TRDA Entrada Therapeutics	$8.13 +3.4%	$10.38	$7.10 ▼ $21.79	$305.65M	0.04	123,930 shs	158,883 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-2.14%	-5.05%	-0.27%	+7.64%	+200.41%
AMPH Amphastar Pharmaceuticals	+1.57%	-0.72%	-14.66%	-34.59%	-41.70%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+113.45%
TRDA Entrada Therapeutics	+3.44%	+3.57%	-22.28%	-35.93%	-33.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.8858 of 5 stars	3.5	1.0	0.0	4.2	2.9	2.5	0.6
AMPH Amphastar Pharmaceuticals	4.3712 of 5 stars	3.0	3.0	0.0	3.7	3.3	4.2	1.3
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	3.1144 of 5 stars	3.6	2.0	0.0	0.0	4.2	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	3.00	Buy	$9.40	28.24% Upside
AMPH Amphastar Pharmaceuticals	2.00	Hold	$43.50	86.30% Upside
CALT Calliditas Therapeutics AB (publ)	2.00	Hold	$39.25	-1.88% Downside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	215.70% Upside

Current Analyst Ratings Breakdown

Latest TRDA, CALT, AMPH, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/31/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/21/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00 ➝ $9.00
3/21/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $32.00
2/25/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
2/20/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $11.00
2/13/2025	ADPT Adaptive Biotechnologies	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$10.00 ➝ $12.00
2/4/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$66.00 ➝ $36.00
2/4/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
1/28/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$5.50 ➝ $7.50

(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	6.09	N/A	N/A	$1.37 per share	5.35
AMPH Amphastar Pharmaceuticals	$731.97M	1.52	$3.26 per share	7.17	$13.35 per share	1.75
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
TRDA Entrada Therapeutics	$210.78M	1.45	N/A	N/A	$7.26 per share	1.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$1.09	N/A	N/A	N/A	-89.12%	-64.65%	-26.45%	5/1/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$137.54M	$3.06	7.78	7.10	2.19	21.80%	26.44%	11.89%	5/6/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
TRDA Entrada Therapeutics	-$6.68M	$1.91	5.11	N/A	N/A	25.53%	16.11%	10.39%	5/6/2025 (Estimated)

Latest TRDA, CALT, AMPH, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	AMPH Amphastar Pharmaceuticals	$0.66	N/A	N/A	N/A	$173.29 million	N/A
5/6/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	N/A	N/A	N/A	$10.98 million	N/A
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	N/A	N/A	N/A	$42.13 million	N/A
2/27/2025	Q4 2024	TRDA Entrada Therapeutics	-$0.66	$0.03	+$0.69	$0.03	$11.95 million	$12.25 million
2/11/2025	Q4 2024	ADPT Adaptive Biotechnologies	-$0.27	-$0.23	+$0.04	-$0.23	$46.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.89	2.81
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
TRDA Entrada Therapeutics	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
AMPH Amphastar Pharmaceuticals	65.09%
CALT Calliditas Therapeutics AB (publ)	2.83%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.20%
AMPH Amphastar Pharmaceuticals	27.10%
CALT Calliditas Therapeutics AB (publ)	2.20%
TRDA Entrada Therapeutics	7.59%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	148.58 million	138.43 million	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.50 million	35.05 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
TRDA Entrada Therapeutics	110	37.60 million	34.58 million	Optionable

TRDA, CALT, AMPH, and ADPT Headlines

Recent News About These Companies

Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

April 17 at 3:10 AM | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.

April 16 at 3:48 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Has $3.85 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

April 11, 2025 | marketbeat.com

HC Wainwright Issues Negative Estimate for TRDA Earnings

April 5, 2025 | marketbeat.com

HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA)

April 1, 2025 | marketbeat.com

Entrada Therapeutics Receives UK Approval To Start Phase 1/2 Trial Of ENTR-601-45 For DMD

March 26, 2025 | nasdaq.com

Entrada receives authorization in the UK to initiate ELEVATE-45-201 study

March 25, 2025 | markets.businessinsider.com

Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK

March 24, 2025 | msn.com

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

March 24, 2025 | globenewswire.com

Connor Clark & Lunn Investment Management Ltd. Reduces Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

March 20, 2025 | marketbeat.com

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

March 3, 2025 | finance.yahoo.com

Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM

March 1, 2025 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)

February 28, 2025 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Viridian Therapeutics (VRDN) and Definitive Healthcare Corp (DH)

February 28, 2025 | markets.businessinsider.com

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

February 27, 2025 | zacks.com

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025 | globenewswire.com

Entrada Shares Climb After FDA Removes Hold on Muscular Dystrophy Treatment

February 25, 2025 | marketwatch.com

Entrada Therapeutics, Inc.: Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

February 24, 2025 | finanznachrichten.de

Entrada’s 2-year ordeal ends as FDA lifts hold on DMD drug

February 24, 2025 | fiercebiotech.com

Entrada announces FDA removal of clinical hold on ENTR-601-44

February 24, 2025 | markets.businessinsider.com

Entrada Therapeutics Inc (TRDA) Receives a Buy from Roth MKM

February 24, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, CALT, AMPH, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$7.33 -0.16 (-2.14%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$7.34 +0.00 (+0.07%)

As of 04/17/2025 06:20 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.35 +0.36 (+1.57%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$23.32 -0.03 (-0.11%)

As of 04/17/2025 04:07 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 04/16/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Entrada Therapeutics NASDAQ:TRDA

$8.13 +0.27 (+3.44%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$8.14 +0.00 (+0.06%)

As of 04/17/2025 04:42 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time